Table 1

Overview of the studies published by authors consulted when planning the IPD meta-analysis

Study

Period

N

Intervention

Primary outcome


Briery[11]

06/04-06/10

30

250 mg 17-OPHC or placebo

delivery before 35 completed weeks' of gestation


Cetingoz[10]

12/04-02/07

67

100 mg vaginal progesterone or placebo

delivery before 37 weeks


Lim[12]

08/06-07/09

654

250 mg 17-OHPC in 1 mL castor oil or placebo

composite outcome (Severe RDS, BPD, IVH grade III or worse, NEC, proven sepsis or death before discharge)


Combs[7]

11/04-02/10

240

250 mg 17-OHPC or placebo

composite outcome (RDS, Oxygen therapy at 28d, Neonatal sepsis, Pneumonia, IVH grade III or worse, periventricular leukomalacia, NEC, retinopathy of prematurity, asphyxia)


Nassar[13]

10/06-10/10

290

250 mg 17-OPHC or placebo

frequency of delivery prior to completed 37 weeks of gestation (259 days)


Norman[9]

12/04-04/08

500

Vaginal progesterone gel 90 mg or placebo

delivery or intrauterine death before 34 weeks of gestation


Rode[14]

06/06-09/10

650

200 mg vaginal progesterone of placebo

incidence of delivery < 34 weeks


Rouse[8]

04/04-02/06

661

250 mg 17-OHPC in 1 mL castor oil or placebo

composite outcome (delivery or fetal death before 35 completed weeks of gestation)


Rozenberg[15]

06/06-06/10

160

500 mg 17-OPHC or no treatment

Interval between inclusion and delivery


Serra[16]

01/06-05/08

246

200 mg or 400 mg vaginal progesterone or placebo

Preterm birth rate (< 37 weeks)


Schuit et al. BMC Pregnancy and Childbirth 2012 12:13   doi:10.1186/1471-2393-12-13

Open Data